Â鶹ÊÓƵ

Formerly NOHMs Technologies, the company combines proprietary electrolyte with a newly developed silicon anode design for a low-cost, high-performance and safer lithium-ion battery. In commercializing these latest silicon anode technologies, Sionic will collaborate with Mechanical Engineering Professor Sehee Lee’s lab and team of postdocs at the CU Boulder. Over the past decade at the university, Dr. Lee’s team has created a legacy of Li-ion battery innovations that help drive the adoption of energy storage in products and their positive impact on climate change.

Researchers at CU Boulder have created a platform that can develop effective and highly specific peptide nucleic acid therapies for use against any bacteria within just one week. The Facile Accelerated Specific Therapeutic (FAST) platform was created by Associate Professor Anushree Chatterjee and her team within the Department of Chemical and Biological Engineering.

CU Boulder spinout ColdQuanta, the leader in Cold Atom Quantum Technology, has been awarded two development contracts from U.S. Government agencies worth $2.55M in total. Both projects are based on the company's Quantum Coreâ„¢ technology that uses atoms cooled to a temperature of nearly absolute zero, and lasers to manipulate and control the atoms with extreme precision.

CU Boulder spinout SomaLogic Inc. is beginning a merger with a special purpose acquisition company CM Life Sciences II that would add up to $651 million in new funding to the company’s books, and make it Colorado’s latest unicorn. The deal values SomaLogic at $1.23 billion before going public, granting it unicorn status as a privately held company worth more than $1 billion.

Inscripta, Inc., the digital genome engineering company, today announced the first commercial shipment of its Onyxâ„¢ platform and the closing of a $150 million Series E financing round led by Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc.

TissueForm seeks to improve quality-of-life outcomes at lower costs for patients suffering from tissue disease, damage, or aging through stem cell and matrix-based therapies. The company—founded by Jeanne Barthold, PhD, and CU Boulder Mechanical Engineering Associate Professor Corey Neu—is no stranger to the pitch competition circuit. TissueForm won $125,000 in Venture Partners' 2018 Lab Venture Challenge and took home multiple awards and more than $20,000 in CU Boulder's New Venture Challenge 11. 

CU spinouts Sachi Bioworks, Inc. and Vesicle Therapeutics, Inc. were two of four Colorado companies that pitched for the opportunity to receive Amgen mentoring and a $5,000 Amgen grant. The pitch event winner, SiVEC Biotechnologies, is an R&D company spun out of Colorado State University and based in Fort Collins. SiVEC is developing a platform technology for the manufacture and delivery of nucleic acids and holds a portfolio of intellectual property with relevance to human and animal health. The company was also a participating venture in the Venture Partners-hosted 2020 Destination Startup® event.

ColdQuanta, a CU Boulder spinout company co-founded by Physics Professor Dana Anderson, is a fast-growing startup focused on Cold Atom Quantum Technology, a scalable, versatile, and commercially viable area of quantum tech. Caruso’s involvement with the company began late last year, as he joined as an investor. After additional conversations with the leadership team, Caruso saw an opportunity to help.

LongPath Technologies, Inc. has been awarded $5 million from the U.S. Department of Energy’s Advanced Research Projects Agency-Energy (ARPA-E). The award will support the commercial scaling of LongPath’s innovative approach to continuous emissions monitoring and mitigation from the oil and gas sector, including the launch of Basin-SCAN (Basin Scale Continuous oil and gas Abatement Network).

OnKure, a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, announced that it has raised $55 million in a Series B financing. Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.